Determination of IL-6 and CRP in Patients with Type Two - Diabetes Mellitus in Baghdad/ Iraq by Ali , Ekhlass N. et al.
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (3): 2019 
 
© Journal of University of Babylon for Pure and Applied Sciences (JUBPAS) by University of Babylon is licensed under a Creative 
Commons Attribution 4. 0 International License 
 
302 
 
Determination of IL-6 and CRP in Patients with 
Type Two - Diabetes Mellitus in Baghdad/ Iraq 
 
Ekhlass N. Ali   Ashwaq A. Khadem   Haidar J. Muhammed 
Department of Biology, College of Science, University of Al-Mustansiriyah, Baghdad, 
Iraq 
Eklassnoori@yahoo.com 
lion_hjm@yahoo.com 
http://uomustansiriyah.edu.iq 
 
 
 
Abstract  
Diabetes mellitus (DM) type Two is a major worldwide health problem leading to an increase 
mortality and serious morbidity. Immunological disturbances involving the cell mediated immune 
system and improper-lymphocyte function contributes to the path physiological of type Two- DM. The 
study consist of 50 subjects, ages ranging between (15-85) years who attended to Al-Kazimaih medical 
hospital in Baghdad/Iraq which divided in to two groups; the first group consists 35 patient  (20 
females and 15 male) and the second 15 (5 female and 10 males) normal healthy as a control. The 
patients with type Two -DM were detected for IL-6 and CRP markers so as for control by ELISA test 
and agglutination test respectively. The results revealed that’s no significant differences (p≥0.05) 
between the level of CRP in patients type Two- DM and level of CRP in control. So as there were 
significant differences (p≤0.05) between the levels of IL-6 concentrations in type Two- DM and control 
represented by increase of IL- 6 in control than in patients. This study aimed to assess and compare the 
level of serum IL-6 and CRP in patient of type Two- DM in Iraqi patients in Baghdad city. 
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Introduction 
Diabetes mellitus is as an abnormal metabolic condition which caused by 
complications and inadequate insulin action. There are two types of diabetes, type one 
which known as insulin dependent diabetes mellitus (IDDM), and Type two which is 
non-insulin dependent diabetes mellitus (NIDDM) [1]. The characterization of 
pathogenesis of type Two- DM by a combination of insulin resistance at the level of 
muscles, fatty acids and failure of endocrine of pancreatic β-cells to equivalent for the 
increased insulin demand [2]-[3]. Type Two- DM was estimated to affect 15 million 
Americans and which was dramatically increasing in incidence [4]-[6]. The main 
physiological abnormalities are insulin resistance and impaired insulin secretion [7]-
[9].  
An accumulating body of evidence suggests that inflammation may be play a 
crucial intermediary role in pathogenesis, thereby linking diabetes with a number of 
commonly coexisting conditions thought to originate through inflammatory 
mechanisms [10]. 
     Data studies, suggest that interleukin 6 (IL-6) and C-reactive protein (CRP), tow 
sensitive physiological markers of subclinical systemic inflammation, are associated 
with hyperglycemia, insulin resistance and overt type Two- DM [10]-[11]. Indeed, 
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recently studies postulated that type Two- DM, may represents a disease related the 
innate immune system (12) that a hypothesis of a particular interest because both of 
these inflammatory biomarkers (IL-6) and (CRP) which also are known to predict the 
development of cardiovascular disease in otherwise healthy populations [13]-[14]. 
Originally it was identified as IL-6 as a factor that induces the final maturation of B- 
cells into plasma cells. Also is involved in diverse biologic processes such as the 
activation of T cells, induction of the acute-phase response, stimulation of the growth 
and differentiation of hematopoietic precursor cells [15]. Another signs with more 
characters for inflammation in the body represented by (C) reactive protein (CRP) 
[16]. A detection tests for CRP are broadly corresponding and assessed for monitoring 
inflammation of cases and response for drug of inflammatory and immunological 
diseases such as rheumatoid arthritis. In addition, a CRP measurement has a practical 
test which a value tested when acute viral or bacterial infection is suspected [17].  The 
study was referred to investigate association of inflammation markers IL-6 and CRP 
in patients with type Two- DM and measurement of fasting glucose comparing with 
healthy control.  
 
Material and Methods         
Sample collection  
      The study content 50 patients afflicted with diabetic mellitus, their age ranging 
(15-85) years that attended from Al-kazimain Teaching Hospital in Baghdad/Iraq 
during the period of October 2015 until February 2016. The quesionering of the 
patients involving patient`s name, genus, type therapy, age and if accompanying 
disease were recorded. The patient`s samples were compared with a total of 15 
healthy (person volunteers) as a control with age of the patients group which were 
included in the present study. A venous blood samples were taken from the patients 
using a plastic disposable syringes (5ml) .The blood samples were centrifugation at 
(3000 rpm) for 15 min for sera separation which were stored in frozen at (-20C°) until 
assayed for markers detection represented by IL-6 and CRP(18) explained by: 
Laboratory assessment  
      The concentration of IL-6 was estimated in the separated sera by ELISA test as 
indicated by the procedure provided by the manufacturer (Koma Biotech 
Ink/Korea).The bio-source IL-6  is a solid phase are present in the specimens react 
with antibodies (MAb1) covered on the micro titer wells and with a antibody (MAb2) 
labeled with (HRP). While the determination of CRP in patients' sera samples by 
agglutination test according to (BioSystem, REF 31311).  The statistically results for 
this study used an Excel 2010 program, by using Minitab software Version 6. 
 
Result and Discussion 
Diabetes mellitus is a pancreatic endocrine disease defects on human body is a 
leading cause of mortality worldwide. It is characterized as a type Two- DM resulting 
from interaction of hereditary and environmental  conditions  that  lead to a 
combination of insulin resistance complication in insulin related glucose defective 
secretion and insulin by pancreatic B-cell. The results of this study showed non-
significant change in CRP in control and in group of patient's case with type Two - 
DM by probability of (p≤0.05). The baseline characteristics of patients diagnosed 
with diabetes compared with control which were shown in table (1) represented by 
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genders of two groups  of  patients and control  and median age which were  50 years 
in male and  39 years for female, whereas  for control was 55 years for male and 62 
years for females .The study denoted that  24 patients of type two - DM have  CRP 
(+ve) and 11 samples CRP( –ve). 
Table (1): Explain the percentage of age and gender mean and CRP test. 
Total 
 
CRP +VE 
N(%) 
CRP-ve 
N(%) 
median age Gender (%) 
 
Groups 
15 
 
13(86.7) 
 
2(13.3) 
 
M 50Y/F39 Y 
 
F 5(33.4)/M10(66.6) 
 
Control 
35 
 
24(68.6) 
 
11(31.4) 
 
M 55Y /F 62 Y 
 
F 20(57.2)/M15(42.8 
 
Patient 
 
 
There were no significant differences in blood sugar level in type two - DM 
(p≥0.05) between CRP+ve and CRP-ve, while there was significant difference 
(p≤0.05) among IL-6 level for CRP-ve and CRP+ve patient as shown in table (2). 
Table (2): Represent significant differences of blood sugar for IL-6 and CRP 
value for studied groups. 
     
PV F test 
CRP + (N 24) CRP - (N 11) 
Test 
Mean ±SD Mean ±SD 
0.9 (NS) 0.01 282.6±64.8 285.5±68.8 B SUGAR 
0.041 (S ) 0.7 8.14±4.53 7.74±4.22 IL-6 pg/ml 
 
The study indicate IL-6 level not correlated to CRP (+ve) and CRP (-ve) 
(p≥0.05) as show in table (3) and figure (1). 
 
Table (3): Correlation between IL-6 and blood sugar in CRP+VE and CRP –VE 
in diabetic patient 
 Pearson correlation P-Value Result 
CRP –VE (11) 
 
0.191 0.573 NS* 
CRP +VE (24) 0.14 0.557 NS 
*No- significant 
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Figure (1):Correlation between IL-6 in blood sugar for CRP (+ve) and CRP(-ve) 
in type Two- DM patients. 
The compression  in IL-6 level between patient and control group was shown in 
figure -2  which indicate that patients of type Two - DM appeared low level of IL-6 
than normal healthy control , the decrease in IL-6 level may be due to the depressed 
cell mediated  immunity in the patients due to intake of medicines to control their 
blood sugar [18]. 
 
 
 
 
 
 
 
 
 
Figure (2): Serum concentration of IL-6 pg/ml in type Two- DM patients and 
control. 
Finally, it's possibly that elevated CRP levels many largely reflect an innate 
system of macrophage so as adipocyte activation for instance, IL-6 and downstream 
CRP  production may be associated with the core lease of other pathogenic substances 
arising from otherwise stimulated adipocytes [19]-[20] elevated CRP reflect the 
balanced altered and modification of cell mediated immunity in addition of  adipocyte 
function, the ready availability of reliable and sensitive markers of this process may 
represent a novel approach for early identification . 
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Conclusion 
The result of  present study suggest and support a possible role for inflammation 
and pathogenesis of type two- DM, in which elevated levels of C-reactive protein and 
interleukin-6. 
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ةصلاخلا 
( يركسلا ءاد دعي(DM Diabetes mellitus  نمضتت . توملا و للاتعلاا ىلا يدؤي يذلا ةيحص ةلكشمك ايملاع فورعملا
 ةيفمللا ايلاخلل ةيولخلا ةيعانملا ةباجتسلاا ضرملل ةيعانملا تابارطضلااT- cells يجولويسفلا راسملا يف مهاست يتلاPath 
physiological l  يناثلا عونلا نم يركسلا ضرمل(Two- DM)  Diabetes   mellitus ( ةساردلا تلمش .50 حوارتت درف )
( نيب مهرامعا15-85  تنمضت ىلولاا نيتعومجم ىلا دارفلاا تمسقو دادغب يف يميلعتلا ةيمظاكلا ىفشتسم ىلا اورضح نيذلا ةنس )
(35(  ضيرم )20  و ىثنا15 ( ةيناثلا ةعومجملاو )لجر15 نيكولرتنا صحف مت . ةرطيسك  ءاحصلاا نم درف )6 - IL توربلا و ني
 لاعفلاC- ((CRP  ءاحصلااو يركسلا ىضرم نم لكل يونعم فلاتخا دوجو مدعب ةساردلا تراشا دقف .(p≥0.05)   نم لك نيب
CRP (-ve-)  وCRP (+ve)  يونعم فلاتخا دوجوب كلذكو يركسلا مدلا يف(p≥0.05)    نيكولرتنلاا  تايوتسم يفIL 6 -  يف
تفده دقل .ءاحصلأاو يركسلا ىضرملا ساردلا نيكولرتنا ةنراقمو مييقت ة6-  IL لاعفلا نيتوربلا وC- (CRP)  يف يركسلا ىضرم يف
.دادغب ةنيدم يف نييقارعلا ىضرملا 
ةلادلا تاملكلا :م ،يركسلا ءادنيكولورتنلاا تايوتس.لاعفلا نيتوربلا ، 
 
